UNSPSC 51171835: Casopitant

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3B03KPM27L. European Medicines Agency schedules Casopitant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32122. Casopitant generally arises in the molecular formula C30H35F7N4O2. The term CASOPITANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56.) Most nations schedule Casopitant under HS 29335990 and SITC 51576.

As of Q4 2014, CASOPITANT remains the US FDA Preferred Term for this commodity. Casopitant bears US NLM identifiers UMLS ID C2347566 and NCI Concept Code C71635. SMILES: CC1CC(CCC1[C@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3CC(CC(C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C)F.

UNSPSC 51171835 Casopitant, a Commodity code, represents pharmaceutical products procured by state and local health, criminal justice, and human services agencies for offender drug testing programs, pharmacy benefit initiatives, and multi-state cooperative pharmaceutical distribution. State and local governments buy casopitant—a neurokinin-1 receptor antagonist primarily used in antiemetic therapy—as part of broader pharmaceutical procurement or specialized testing and treatment programs. The issuing bodies include county criminal justice departments, state health and human services commissions, and multi-state cooperative purchasing alliances coordinating procurement across multiple states and jurisdictions.

Recent solicitation activity shows limited direct casopitant procurement but significant pharmaceutical-category activity in allied areas. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years with optional renewal, encompassing immunoassay screening, LC/MS/MS or GC/MS confirmation, and alternative testing methodologies but focused on test administration rather than pharmaceutical products themselves. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 seeking market intelligence on direct-to-manufacturer prescription fulfillment programs without specifying casopitant or particular pharmaceutical classes. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, with contract term commencing July 1, 2026. Recent activity concentrates in Texas and Minnesota, with MMCAP's scope extending to participating states including Oregon. The code shows sparse direct casopitant demand signals; procurement under this code may be absorbed into broader generic pharmaceutical or health-system purchasing vehicles rather than solicited discretely.